Clinical efficacy of febuxostat combined with hydrochlorothiazide in the treatment of chronic kidney disease
Objective To explore the clinical effect of febuxostat combined with hydrochlorothiazide in the treatment of chronic kidney disease.Methods 120 patients with chronic kidney disease were selected as the subjects of this study.They were divided into the observation group and the control group according to the random numerical table,with 60 cases in each group.The patients in the control group were treated with hydrochlorothiazide alone,and the patients in the observation group were treated with hydrochlorothiazide combined with febuxostat.Comparison was made on treatment effect,incidence of adverse reactions,serum cystatin C(Cys-C),and N-terminal pro brain natriuretic peptide(NT-proBNP),renal function[blood urea nitrogen(BUN),serum creatinine(SCr),urinary protein(Upro)]between the two groups.Results The total effective rate of the observation group was 96.67%,which was higher than 83.33%of the control group(P<0.05).Before treatment,there were no significant differences in the levels of Cys-C and NT-proBNP between the two groups(P>0.05).After treatment,the levels of Cys-C and NT-proBNP in both groups were lower than those before treatment;the observation group had Cys-C of(1.20±0.15)mg/L and NT-proBNP of(1142.38±26.75)pg/ml,which were lower than(1.52±0.29)mg/L and(1429.38±31.36)pg/ml in the control group(P<0.05).Before treatment,there were no significant differences in BUN,SCr and Upro levels between the two groups(P>0.05).After treatment,BUN,SCr and Upro levels decreased in both groups;the observation group had BUN of(8.48±2.15)mmol/L,SCr of(117.25±25.64)μmol/L,and Upro of(1.30±0.52)g/24 h,which were lower than(10.52±1.30)mmol/L,(153.19±41.43)μmol/L,and(1.88±0.40)g/24 h in the control group(P<0.05).The incidence of adverse reactions in the observation group was 3.33%,which was lower than 16.67%in the control group(P<0.05).Conclusion The clinical effect of febuxostat combined with hydrochlorothiazide in the treatment of chronic kidney disease patients is significant.It can not only improve the levels of Cys-C and NT proBNP,but also improve the renal function of patients with high safety and promote the recovery of patients.
万方数据
维普
